// App-Quantinova.ai

9589 : Phase III randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma.

Researchers

Presenter

  • Bin Lian

Principal Investigators

  • Xin Song

  • Xiaoshi Zhang

  • Di Wu

  • Lu Si

  • Zhihong Chi

  • Xinan Sheng

  • Yan Kong

  • Li Li Mao

  • Li Zhou

  • Xuan Wang

  • Bixia Tang

  • Xieqiao Yan

  • Siming Li

  • Dan Li

  • Jie Dai

  • Xue Bai

  • Cai Li

  • Jun Guo

Medical Centers

  • Peking University Cancer Hospital & Institute, Beijing, China

  • Yunnan Cancer Hospital, Kunming, China

  • Sun Yat-Sen University Cancer Center, Guangdzhou, Guangdong, China

  • The First Hospital of Jilin University, Changchun, China

  • Beijing Sanhuan Cancer Hospital, Beijing, China

  • Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China

  • Peking University Cancer Hospital & Institute, Beijing, China

  • Peking University Cancer Hospital & Institute, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Temozolomide

  • Cisplatin

  • IFN-lambda

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved